Ciprofol + Propofol
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecological Outpatient Surgery
Conditions
Gynecological Outpatient Surgery
Trial Timeline
Jul 26, 2021 → Sep 30, 2021
NCT ID
NCT04958746About Ciprofol + Propofol
Ciprofol + Propofol is a phase 3 stage product being developed by Haisco Pharmaceutical Group for Gynecological Outpatient Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT04958746. Target conditions include Gynecological Outpatient Surgery.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05035069 | Approved | UNKNOWN |
| NCT04958746 | Phase 3 | Completed |
| NCT04294056 | Phase 1 | Completed |
Competing Products
3 competing products in Gynecological Outpatient Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 51 |